Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEN2293 in mild to moderate atopic dermatitis
NCT04737304Phase 2Completed
- Sponsor
- BenevolentAI
- Start
- Oct 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BEN-2293 in atopic dermatitis (AD), sponsored by BenevolentAI. Started Oct 2020; status: completed.
02
Drugs
BEN-2293
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04737304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737304.